Open AccessEnfortumab Vedotin (Padcev)
Author(s) -
Reimbursement Team
Publication year - 2022
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2022.247
Subject(s) - medicine , regimen , urothelial cancer , oncology , chemotherapy , programmed cell death 1 , disease , cancer , pd l1 , immunotherapy , bladder cancer
CADTH recommends that Padcev should be reimbursed by public drug plans for the treatment of advanced or metastatic urothelial cancer (UC) if certain conditions are met.
Padcev should only be covered to treat adult patients with UC who have already received treatment with a platinum-containing chemotherapy regimen, and a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor for advanced or metastatic disease.
Padcev should only be reimbursed if prescribed as monotherapy by a clinician who has experience treating patients with advanced UC and if the price of Padcev is reduced.